Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The investigators conduct the real world study to explore the efficacy and safety of Apatinib in gastric cancer .
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Progress free survival | Progress free survival is defined as the length of time from random assignment to disease progression or to death resulting from any cause other than the progress. | 1 year |
| Measure | Description | Time Frame |
|---|---|---|
| disease control rate | Investigators will assess treatment response according to Response Evaluation Criteria in Solid Tumors 1.1 | 1year |
| Objective tumor response rate | Objective tumor response rate is defined as the percentage of subjects having achieved confirmed Complete Response + Partial Response as best overall response according to radiological assessments |
| Measure | Description | Time Frame |
|---|---|---|
| Quality of life score | Quality of life score is a questionnaire developed to assess the quality of life of cancer patients. | 1year |
| adverse events | adverse events are evaluated according to National Cancer Institute Common Terminology Criteria for Adverse Events v4.0. |
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
patients of gastric cancer in Anhui province
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| guoping sun, doctor | Contact | 0551-62922249 | gpsun_ahmu@126.com |
| Name | Affiliation | Role |
|---|---|---|
| China Anhui | The First Affiliated Hospital of Anhui Medical University | Study Chair |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| First Affiliated Hospital of Anhui Medical University | Recruiting | Hefei | Anhui | 230000 | China |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 32821164 | Derived | Peng W, Zhang F, Wang Z, Li D, He Y, Ning Z, Sheng L, Wang J, Xia X, Yu C, Wang Z, Zhao Y, Liang H, Hu B, Sun C, Wang D, Cheng Y, Pan M, Xia L, Guo X, Zhang Y, Hu Z, Li X, Lu L, Zhang J, Qian H, Xie H, Sun G. Large Scale, Multicenter, Prospective Study of Apatinib in Advanced Gastric Cancer: A Real-World Study from China. Cancer Manag Res. 2020 Aug 6;12:6977-6985. doi: 10.2147/CMAR.S249153. eCollection 2020. | |
| 32441892 |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D013274 | Stomach Neoplasms |
| ID | Term |
|---|---|
| D005770 | Gastrointestinal Neoplasms |
| D004067 | Digestive System Neoplasms |
| D009371 | Neoplasms by Site |
| D009369 | Neoplasms |
Not provided
Not provided
Not provided
Not provided
Not provided
| 1year |
| overall survival | overall survival is defined as the length of time from random assignment to death or to last contact. | 3year |
| Disease-free survival | Disease-free survival is defined as the length of time from the date of randomization to the date of first documentation of relapse of gastric cancer or any other type of cancer or death. | 1 year |
| 1year |
| Derived |
| Du Y, Cao Q, Jiang C, Liang H, Ning Z, Ji C, Wang J, Zhou C, Jiang Z, Yu C, Li L, Zhao Y, Xu Y, Xu T, Hu W, Wang D, Cheng H, Wang G, Zhou J, Wang S, Zhang Y, Hu Z, Li X, Lu D, Zhang J, Xie H, Sun G. Effectiveness and safety of low-dose apatinib in advanced gastric cancer: A real-world study. Cancer Med. 2020 Jul;9(14):5008-5014. doi: 10.1002/cam4.3105. Epub 2020 May 22. |
| D004066 |
| Digestive System Diseases |
| D005767 | Gastrointestinal Diseases |
| D013272 | Stomach Diseases |